References
- Wei CY , LeeMT , ChenYT . Pharmacogenomics of adverse drug reactions: implementing personalized medicine . Hum. Mol. Genet.21 ( R1 ), R58 – R65 ( 2012 ).
- Severino G , Del ZompoM . Adverse drug reactions: role of pharmacogenomics . Pharmacol. Res.49 , 363 – 373 ( 2004 ).
- Johnson JA , GongL , Whirl-CarrilloMet al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing . Clin. Pharmacol. Ther.90 , 625 – 629 ( 2011 ).
- Scott SA , SangkuhlK , GardnerEEet al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450–2C19 (CYP2C19) genotype and clopidogrel therapy . Clin. Pharmacol. Ther.90 , 328 – 332 ( 2011 ).
- Crews KR , GaedigkA , DunnenbergerHMet al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update . Clin. Pharmacol. Ther.95 , 376 – 382 ( 2014 ).
- Goldstein J . Clinical relevance of genetic polymorphisms in the human CYP2C subfamily . Br. J. Clin. Pharmacol.52 ( 4 ), 349 – 355 ( 2001 ).
- Van Booven D , MarshS , McLeodHet al. Cytochrome P450 2C9-CYP2C9 . Pharmacogenet. Genomics20 ( 4 ), 277 – 81 ( 2010 ).
- Scott S , SangkuhlK , ShuldinerARet al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19 . Pharmacogenet. Genomics22 ( 2 ), 159 – 165 ( 2012 ).
- Owen RP , SangkuhlK , KleinTE , AltmanRB . Cytochrome P450 2D6 . Pharmacogenet. Genomics19 ( 7 ), 559 – 562 ( 2009 ).
- US FDA . Guidance for industry: pharmacogenomic data submissions – companion guidance. US Department of Health and Human Services, Food and Drug Administration (2007) . www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079855.pdf .
- EMA . Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products. EMA/CHMP/37646/2009. Committee for Medicinal Products for Human Use, European Medicine Agency (2012) . www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500121954.pdf .
- Sica DA . Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats . Drugs62 ( 3 ), 443 – 462 ( 2002 ).
- Leichter SB , ThomasS . Combination medications in diabetes care: an opportunity that merits more attention . Clin. Diabetes21 ( 4 ), 175 – 178 ( 2003 ).
- Podolsky SH , GreeneJA . Combination drugs – hype, harm, and hope . N. Engl. J. Med.356 ( 6 ), 488 – 491 ( 2011 ).
- Hutchins V , ZhangB , FleurenceRL , KrishnarajahG , GrahamJ . A systematic review of compliance, treatment satisfaction and costs, in fixed-dose combination regimens in Type 2 diabetes . Curr. Med. Res. Opin.27 ( 6 ), 1157 – 1168 ( 2011 ).
- Gupta AK , ArshadS , PoulterNR . Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis . Hypertension55 , 399 – 407 ( 2010 ).
- Deharo P , QuiliciJ , BonnetGet al. Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome . Int. J. Cardiol.172 ( 1 ), e1 – e2 ( 2014 ).
- Thom S , PoulterN , FieldJet al. UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial . JAMA310 ( 9 ), 918 – 929 ( 2013 ).
- Bangalore S , KamalakkannanG , ParkarS , MesserliFH . Fixed-dose combinations improve medication compliance: a meta-analysis . Am. J. Med.120 , 713 – 719 ( 2007 ).
- Woodcock J , GriffinJP , BehrmanRE . Development of novel combination therapies . N. Engl. J. Med.364 ( 11 ), 985 – 987 ( 2011 ).
- PILL Collaborative Group , RodgersA , PatelAet al.An international randomized placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk . PLoS ONE6 ( 5 ), e19857 ( 2011 ).
- US FDA . Guidance for industry – co-development of two or more unmarketed investigational drugs for use in combination . www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM236669.pdf .
- Drugs at FDA resources page . www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm .
- Nuedexta 20/10 Package Label . Avanir Pharmaceuticals, Inc. 5.8 CYP2D6 poor metabolizers (2010) . www.drugs.com/pro/nuedexta.html#LINK_bc9d5dec-36fa-41f9-9542-da1c4de2d079 .